Previous Article | Next Article ![]()
Journal of Virology, April 2000, p. 3058-3066, Vol. 74, No. 7
Department of Medicine, Johns Hopkins
University School of Medicine, Baltimore, Maryland
21205,1 and Department of Virology
and Immunology, Southwest Regional Primate Research Center, Southwest
Foundation for Biomedical Research, San Antonio, Texas
782272
Received 18 August 1999/Accepted 21 December 1999
The putative envelope 2 (E2) gene of hepatitis C virus (HCV)
contains a highly variable region referred to as hypervariable region 1 (HVR1). We hypothesized that this genetic variability is driven by
immune selection pressure, rather than representing the accumulation of
random mutations in a region with relatively little functional
constraint. To test this hypothesis, we examined the E2 sequence of a
human inoculum that was passaged through eight chimpanzees, which
appear to have a replicative rate (opportunity for chance mutation)
similar to that of humans. Acute-phase plasma samples from a human (the
inoculum) and six of eight serially infected chimpanzees were studied.
For each, 33 cloned cDNAs were examined by a combined
heteroduplex-single-stranded conformational polymorphism assay to
assess quasispecies complexity and optimize selection of clones with
unique gel shift patterns (clonotypes) for sequencing. The sequence
diversity of HCV was significantly lower in the chimpanzees than in the
humans, and during eight serial passages there was no change in the
sequence of the majority clonotype from each animal examined.
Similarly, the rates of protein sequence altering (nonsynonymous)
substitution were lower in the chimpanzees than in the humans. These
findings demonstrate that nonsynonymous mutations indicate selection
pressure rather than being an incidental result of HCV replication.
An estimated 170 million people
worldwide are infected with hepatitis C virus (HCV) (4).
More than 80% of infections result in persistent viremia, which may be
associated with chronic hepatitis, cirrhosis, liver failure, and
hepatocellular cancer (3, 41, 44). HCV-associated disease is
responsible for more than 10,000 deaths each year in the United States
alone, and this mortality is expected to rise (8). Because
of limitations of in vitro replication systems, studies of HCV
pathogenesis have been limited to observation of natural infection of
humans and experimental infection of chimpanzees.
The chimpanzee is the best experimental model of HCV infection. HCV
does not grow efficiently in tissue culture, and the only other
candidate model is a tree shrew that is too small to permit adequate
sampling with current technology (52). In chimpanzees, HCV
replication has been demonstrated within days of experimental infection, and the potential for reinfection has been demonstrated (14, 15, 37, 51). Serum HCV RNA levels and the extent of
hepatic HCV involvement are similar in chimpanzees and humans, suggesting that replication rates are similar (1). The
chimpanzee has also been used to test the infectivity of HCV clones and
vaccine candidates. However, Bassett et al. recently demonstrated that the natural history of HCV infection in a cohort of experimentally infected chimpanzees differed from what is typically found in humans
(5, 6). These chimpanzees had a higher rate of clearance of
viremia, lower rate of antibody production to envelope proteins, and
lower rate of envelope amino acid change. Similarly, others have
reported little change in E2 amino acid sequence in chimpanzees infected with molecular clones (24). In contrast,
comparisons of E2 sequences in humans (both within and between infected
subjects) reveal substantial heterogeneity, especially in the
27-amino-acid region at the N terminus of E2 that has been called
hypervariable region 1 (HVR1).
HCV variants coexist in each infected individual as a swarm of
genetically distinct but related variants, called a quasispecies (10-12, 23, 25). HCV sequences can shift rapidly during
chronic human infection (20) and interferon therapy
(31), consistent with the predicted behavior of a
quasispecies in a rapidly changing selective environment dominated by
the immune system (40). Another prediction of the
quasispecies model is that the master (or most common) sequence in the
quasispecies will not change in a stable environment, while changes in
minor variants will continue to occur. Evidence from immunosuppressed
individuals, in whom the pace of sequence variation is reduced,
suggests that this prediction applies to HCV (7, 28, 42).
If HCV persists by escaping the immune response through sequence
variation, then that sequence variation will reveal important characteristics of the immune response. If, however, persistence is due
to other factors and sequence variation is simply the random product of
an error-prone polymerase and a rapidly replicating virus
(47), then sequence variation will always occur when HCV is
allowed to replicate, and sequence variation will be uninformative except to define areas tolerant of sequence variation.
We hypothesized that despite an HCV replication rate similar to that in
humans (37), reduced immune pressure in chimpanzees would
result in limited sequence variation of HCV. To test this hypothesis,
we studied the HCV quasispecies in a cohort of animals through which
HCV was serially passed and in two animals with persistent infection.
The serial passage experiment was initiated using a well-characterized
strain of HCV (H77), obtained via plasmapheresis from a patient during
acute HCV infection (5).
Using a highly sensitive method for detection of distinct variants, we
determined the complexity of the quasispecies in each specimen and
selected representative cloned cDNAs for sequence analysis. Sequences
from these specimens revealed minimal changes in the envelope sequence
examined on transfer from human to chimpanzee, in serial passage among
chimpanzees, and during chronic infection of chimpanzees. These
findings suggest that passage in chimpanzees does not affect the E2
sequence and that HCV replication does not inherently result in the
accumulation of substitutions in the master sequence.
Study animals.
As part of a study of non-A, non-B hepatitis
(NANBH), chimpanzees were inoculated with human serum as follows (Table
1): animal x007 (passage 1 [P1]) was
inoculated with 102.5 chimpanzee infectious doses of serum
obtained via plasmapheresis from patient H in 1977, designated H77
(2, 17). Weekly assessments for rise in alanine
aminotransferase allowed identification of the acute phase of
infection, and acute-phase serum was used to inoculate the next animal
in the series. Animal x174 (P2) had persistent viremia, whereas the
seven other animals in the passage had transient viremia
(5).
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Hypervariable Region 1 Sequence Stability during
Hepatitis C Virus Replication in Chimpanzees

and
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
TABLE 1.
Characteristics of study subjects
Human subjects. Since 1988, a cohort of approximately 1,350 former and current injection drug users have been followed in Baltimore (46), including 43 subjects who acquired HCV infection during follow-up (45). The viral load trajectories and temporal sequence of HCV RNA and antibody detection for these subjects are described elsewhere (44). The six subjects chosen for this investigation continued to have detectable HCV RNA in the last specimen tested after at least 6 years of semiannual follow-up. The date of infection was estimated by calculating the midpoint between the date of the first specimen in which HCV RNA or antibody was detected and the date of the last prior sample in which evidence of HCV infection was not detected.
Storage of serum and testing for anti-HCV.
Serum samples
were immediately centrifuged, stored for less than 1 week at
20°C,
and subsequently stored at
70°C. They were tested for antibodies to
HCV (HCV EIA [enzyme immunoassay] 2.0; Ortho Diagnostics, Raritan,
N.J.) and, if EIA positive, by strip immunoblot assay (RIBA HCV 2.0;
Chiron Corporation, Emeryville, Calif.) as previously described
(45).
HCV RNA detection. In all HCV seroconverters, the presence of HCV RNA was evaluated in sera collected 6 months before seroconversion, at seroconversion, and during subsequent semiannual visits (median of 8) (44). HCV RNA was initially detected with a quantitative reverse transcriptase PCR assay (AMPLICOR HCV MONITOR; Roche Diagnostic Systems, Branchburg, N.J.), the linear range of which was 500 to 500,000 copies per ml of serum in this and other laboratories (21, 34). For chimpanzees with persistent viremia, HCV RNA was quantitated using the COBAS AMPLICOR 2.0 detection system (Roche Diagnostic Systems). In a comparison of these two methods using paired patient specimens and dilutions of H77, the COBAS method generally gave slightly higher values, but the difference was consistently less than a factor of 10 (A. Valsamakis, personal communication).
Envelope region amplification. HCV RNA characterization was based on examination of 33 cloned cDNAs spanning the 1,026-nucleotide (nt) region thought to encode envelope protein E1 and a segment of E2, including HVR1 (33). RNA was extracted from 100 µl of plasma or serum by using a QIAamp viral RNA mini kit as specified by the manufacturer (Qiagen, Valencia, Calif.). One-fifth of the extract was used to generate cDNA in a 20-µl reaction at 37°C for 1 h with 20 U of Moloney murine leukemia virus reverse transcriptase (Perkin-Elmer, Foster City, Calif.) and first-round PCR reverse primer. The entire 20-µl cDNA synthesis reaction was used for first-round PCR in a 25-µl reaction containing 0.625 U Expand HF polymerase mixture (Boehringer Mannheim, Indianapolis, Ind.), 1.5 mM MgCl2, 0.2 mM deoxynucleoside triphosphates and 0.4 µM primers. The primers (and positions relative to the HCV-1 genome polyprotein [9]) were outer forward (493 to 518; 5'-GCAACAGGGAACCTTCCTGGTTGCTC-3'), outer reverse (1745-1723; 5'-GGGCAGDBCARRGTGTTGTTGCC-3'), inner forward (502-527; 5'-AACCTTCCTGGTTGCTCTTTCTCTAT-3'), and inner reverse (1527 to 1507; 5'-GAAGCAATAYACYGGRCCACA-3'). Degenerate bases are indicated with standard International Union of Pure and Applied Chemistry codes. Ten microliters of the first reaction product was used as template for the inner nested PCR. Thermal-cycling conditions for both the inner and outer reactions were denaturation for 120 s at 94°C, followed by 35 cycles of 15 s at 94°C, 30 s at 65°C, and 60 s at 72°C (during the last 25 cycles, the elongation time was increased by 20 s per cycle).
Cloning of cDNA and complexity analysis of 33 cloned cDNAs by gel
shift.
The 1-kb HCV cDNA product was ligated into vector pCR 2.1 and used to transform INV
F' cells (TA cloning kit; Invitrogen, Carlsbad, Calif.). Transformants were detected per manufacturer's protocol, and cloning efficiency was >90%.
Sequencing of representative cloned cDNAs. To examine each specimen's quasispecies for trends in sequence variation, a subset of cloned cDNAs was identified for sequencing. For each subject, at least three cloned cDNAs were selected for sequencing based on gel shift patterns: two from the majority clonotype, one from each clonotype consisting of more than 10% of the 33 cloned cDNAs examined, and the cloned cDNA with the largest heteroduplex gel shift. Plasmid DNA was isolated from a 3.5-ml broth culture (High Pure plasmid isolation kit; Boehringer Mannheim) according to the manufacturer's protocol. Sequences were determined from this DNA by using universal reverse primers with a PRISM version 2.1.1 automated sequencer (ABI, Foster City, Calif.). Sequences were assembled and edited in Sequencher (Gene Codes, Ann Arbor, Mich.) by a technician who was blinded to our hypotheses. Primer sequences were removed prior to analysis.
Phylogenetic analysis. Sequence alignments were randomly permuted 100 times by using the SEQBOOT program from the PHYLIP package version 3.572c (18, 19). DNA distance matrices were calculated by using the DNADIST program, maximum likelihood model, with a transition-to-transversion ratio of 4.25 (39). Permuted trees were generated using the NEIGHBOR program with random addition, and bootstrap values were obtained by using CONSENSE. Subtype reference sequences used for phylogenetic analysis had the following accession numbers (subtype designations in quotes remain controversial): 1a, AF009606 and M62321; 1b, D90208; 1c, D14853; 2a, D00944; 2b, D10988; 3a, D17763; 4a, Y11604; 5a, Y13184; 6a, Y12083; "7a," D84263; "8a," D84264; "9a," D84265; "10a," D63821; and "11a," D63822. Nonsynonymous and synonymous substitution frequencies were calculated by the method of Nei and Gojobori (27).
Statistical analysis. After examination of the distribution of data, statistical inference was made by using the nonparametric Mann-Whitney test of medians.
Nucleotide sequence accession numbers. The sequences obtained from chimpanzees were submitted to GenBank and assigned accession no. AF230416 through AF230459.
| |
RESULTS |
|---|
|
|
|---|
Amplification and HDA+SSCP analysis. From the six animals (P1, P2, P3, P4, P5, and P8) that comprised the serial eight passage lineage, the acute-phase plasma (collected 4 to 11 weeks after inoculation and representing the inoculum for the next numbered animal) was studied. Specimens collected within 2 weeks of inoculation (designated hyperacute) were also available for study from P4 and P5 (Table 1). Chronic-phase specimens from animals P2 and x304 were studied. Animal P2 sustained chronic viremia 8 years after inoculation with x7 (H77) serum, and x304 sustained chronic viremia 10 years after inoculation with NANBH (HCV-1). The quasispecies complexity was examined by assessing 33 cDNA clones from each specimen using HDA+SSCP. The median clonotype ratio (range) of the acute phase of chimps, 0.27 (0.18 to 0.39), was similar (P > 0.5) to that found in the first RNA-positive specimen from acutely infected humans, 0.39 (0.09 to 0.67).
Detection of persistent clonotypes through passages.
Use of a
common cDNA clone to drive the HDA+SSCP gels permitted comparison of
clonotypes among specimens. Among 198 cloned cDNAs from acute-phase
specimens, 49 distinct patterns (clonotypes) were identified (Fig.
1).
A subset of clonotypes persisted
during multiple passages in chimpanzees (Fig.
2). Clonotype a was the most frequently
detected clonotype in animals P1, P3, P4, P5, and P8, representing 24 to 76% of cloned cDNAs. Clonotype b was detected in animals P1, P3,
P4, and P5. Four clonotypes were observed in three animals each, and
nine clonotypes were detected in two animals. For animals P1, P3, P4,
P5, and P8, 91 to 94% of cloned cDNAs were observed in at least one
other animal. In contrast, the six clonotypes observed for P2 were
distinct from all others. Animals P6 and P7 were not examined.
Therefore, HDA+SSCP analysis indicated the persistence of clonotype a
through chimpanzee passages P1 to P8, with the exception of animal P2,
which was the animal that developed persistent viremia. In contrast to
the persistence of clonotypes during serial passage, acute and chronic
specimens from animals P2 and x304 shared no clonotype (Fig. 1). All of these observations were supported by subsequent sequence analysis (see
below).
|
|
Increase in complexity during infection of chimps and humans.
In each pair of specimens from the same chimpanzee, the complexity of
the quasispecies assessed using the clonotype ratio increased with time
from inoculation or seroconversion, both during the acute phase (0.08 and 0.05 per month in animals P4 and P5) and also during the chronic
phase (0.004 and 0.002 per month in animals P2 and x304). This was also
true of four of the six humans who had clonotype ratio changes of
+0.003, +0.005, +0.006, and +0.007. However, decreasing complexity was
observed in subjects AT and AZ, who had per-month clonotype ratio
changes of
0.007 and
0.004 (P > 0.1 for
comparisons of clonotype ratios and rates of change). Of note, the
infecting subtype of subjects AT and AZ (1b) differed from that of the
other hosts (1a), and subject AT seroconverted for human
immunodeficiency virus during the period of observation. Having found
that human and chimpanzee quasispecies were similar in the number of
distinct variants in both acute and chronic infection, we compared the
substitution rates.
Initial sequence analysis.
By using HDA+SSCP to select
representative cloned cDNAs, 72 distinct cloned cDNAs were identified
for sequencing. To determine the genetic identity of cDNA clones of the
same clonotype, two representative sequences representing the majority
clonotype were compared for each specimen. There were nine differences
among 11 pairs of 390-nt sequences (99.8% identity), and all but one difference represented sporadic substitutions (occurring only once in a
set of related sequences) as defined by Smith et al. (38).
The eight sporadic substitutions were probably artifactual, occurring
at a frequency of 3.1 × 10
5 sporadic substitutions
per site per PCR cycle, consistent with the misincorporation frequency
of the thermostable polymerase and sequencing reactions (38)
and similar to the rate others and we have observed (26,
33). For each majority clonotype, one of the two sequences was
free of sporadic substitutions and was used in all subsequent analyses
to represent that clonotype. In addition, no two cloned cDNAs
identified as being distinct by HDA+SSCP analysis had identical
sequences (data not shown). Therefore, the HDA+SSCP method is both
highly sensitive and specific in detecting differences among cDNA
clones, as previously reported (48). Since the cDNA sequence
of one member of a clonotype represents the other members of that
clonotype, the 72 cDNA sequences that we obtained represented 200 (72.2%) of the 363 cDNA clones examined.
|
Comparison of acute- and chronic-phase sequences. The mean pairwise genetic distance between acute- and chronic-phase sequences was consistently lower in chimpanzees than in humans. This is illustrated by phylogenetic analysis (Fig. 3), which shows shorter branch lengths (lower genetic distance) between acute- and chronic phase sequences from chimpanzees than those from humans. For both chimpanzees with persistent viremia, the mean genetic distance between acute and chronic sequences (interval of 8 to 10 years) was 0.013. In contrast, the mean genetic distance between acute- and chronic-phase sequences for human subject H (interval of 22 years) was 0.093, and in the other six humans (interval of 4 to 7 years) it was 0.044 (range, 0.028 to 0.054). Substitution rates calculated from these data were lower for chimpanzees P2 and x304 (0.0018 and 0.0015 substitutions per site per year) than for human subject H (0.0042) and the other humans (mean, 0.0083; range, 0.0075 to 0.010) (P = 0.055 by Mann-Whitney U test).
In humans, HVR1 is unlike the rest of the HCV genome because nonsynonymous substitutions are as frequent as synonymous substitutions (26, 39), but this was not the case in the chimpanzees in this study. The substitutions observed during chronic infection of chimpanzees were predominantly synonymous, resulting in no change in the amino acid sequence, whereas they were predominantly nonsynonymous (resulting in changes in amino acid sequence) in humans. For chimpanzees P2 and x304, the nonsynonymous substitution frequencies (dN) were 0.011 and 0.012, the synonymous substitution frequencies (dS) were 0.025 and 0.023, and dN/dS ratios were 0.44 and 0.52, respectively. For human subject H, dN was 0.082, dS was 0.13, and dN/dS was 0.65, whereas for the other six humans, mean (range) dN was 0.047 (0.024 to 0.060), mean (range) dS was 0.034 (0.017 to 0.057), and mean (range) dN/dS was 1.7 (0.9 to 3.5). Rates derived from these data (Fig. 4) show that the nonsynonymous rate was higher for humans than for chimpanzees (P = 0.055 by Mann-Whitney U test), synonymous rates varied widely (P > 0.10), and the ratio of these rates was uniformly higher for humans than for chimpanzees (P = 0.055 by Mann-Whitney U test).
|
Detailed analysis of sequences from serial passages. The lack of change in the E2 sequence during eight sequential chimpanzee passages was striking. The majority acute-phase nucleotide sequence for each animal was identical to the majority sequence for the inoculum (H77) strain, except for a single nucleotide change in the third HVR1 codon in animal P2. When all sequenced variants were included in the analysis, there was less than 0.009 weighted genetic sequence distance between any two sequential animals, and from P1 to P8 the weighted genetic distance was 0.0028. This limited variation was not focused in HVR1 as occurs in humans but was distributed evenly across the region sequenced (data not shown).
Figure 5 shows the HVR1 amino acid sequence of the predominant clonotype from each chimpanzee and human specimen. It is notable for the persistence of the majority HVR1 sequence from H77 through all passages (except P2) and the persistence of the majority clonotype sequence in x304. The arginine substitution at residue 3 in all P2 acute-phase sequences was not seen in any other chimpanzee specimen in this study (Fig. 1) but has been described for other chimpanzees infected with H77 (29).
|
| |
DISCUSSION |
|---|
|
|
|---|
In this investigation we demonstrated that HVR1 of two strains of HCV subtype 1a underwent very little sequence variation in chimpanzees, whether assessed during serial passage or between acute and chronic phases. This is a striking finding since substantially greater sequence variation was noted in humans with similar HCV RNA levels, indicating the laboratory methods and number of replication cycles were sufficient to detect change. These results suggest that these HCV-infected chimpanzees exerted more negative selection (suppressing changes in the amino acid sequence of HCV) than humans or less positive selection (driving changes in the amino acid sequence), or both.
Strong negative selection is not a likely explanation for the limited change in E2 protein sequences from chimpanzees, since this would imply that there are greater functional constraints on the E2 protein in chimpanzees than in humans. However, a wide spectrum of E2 sequences can be detected in chimpanzees, suggesting that the observed stability of E2 sequences is not due to restrictions imposed by the host.
Weaker positive selection is a more likely explanation for the observed sequence stability. A number of studies indicate that positive selective forces affect the HCV sequence. In particular, HCV envelope sequence evolution has been correlated with antibody production (22, 35, 49), and lower rates of evolution have been observed in agammaglobulinemic subjects. In addition, HVR-specific antibodies may neutralize HCV infectivity (16, 36, 53). van Doorn and coworkers also demonstrated the temporal correlation of anti-HVR antibody production and amino acid changes in chimpanzees (43). In this regard, it is important to note that the sequence stability observed in this study through the lineage of chimpanzees represented samples taken before the measured humoral and cellular immune response.
The supposition that positive selection drives sequence evolution for HCV is supported by studies of other RNA viruses. There have been a number of investigations correlating cytolytic T-lymphocyte responses with human immunodeficiency virus sequence variation (32, 50). In addition, recent data correlate nonsynonymous sequence changes with escape from dominant cytolytic T-lymphocyte responses in chimpanzees experimentally infected with simian immunodeficiency virus (13). These data indicate that replication alone does not drive amino acid mutation in a quasispecies.
The HDA+SSCP analysis used in this investigation reveals classical quasispecies characteristics of HCV throughout the chimpanzee passage experiment. Each specimen contained a swarm of distinct but related variants. The number of variants (complexity) was similar to that found in acute human HCV infection. In each animal there was a master (most commonly observed) sequence representing 24 to 85% of the 33 variants examined, accompanied by minor variants which were nearly always (>90%) found in another animal, usually the prior or subsequent animal in the passage (Fig. 2), except for animal P2. The master sequence (represented by clonotype a in Fig. 2) did not change during the eight passages, except for a single nonsynonymous substitution in the one animal (P2) that developed persistent viremia. The inoculum for P3 was obtained from P2 18 days prior to the P2 specimen available for this study. Therefore, explanations for the reappearance of clonotype a in P3 include (i) the mutation occurred or became dominant during the 18-day interval, (ii) a reversion mutation occurred in P3, and (iii) clonotype a was present in P2 below the level of detection but was preferentially expanded in P3.
Our findings are limited to the envelope gene region examined. It is possible that significant changes occurred in other regions during the passage experiments or during chronic infection. Nonetheless, full-genome sequence data from 15-month follow-up of two chimpanzees infected with a molecular HCV clone (constructed from H77 sequence) also found little variability in the N terminus of E2 (24). In that study, one animal had a single amino acid substitution in HVR1 at week 51, despite readily detectable anti-HVR1 in both animals.
Although this study involves a relatively large number of chimpanzees, only two strains of HCV were assessed: H77 and NANBH (similar to HCV-1). In addition, both animals with chronic viremia (P2 and x304) received serum from an infected chimpanzee rather than a (possibly more complex) human inoculum. Other studies of chimpanzees infected with different HCV strains or human serum have shown higher rates of substitution (30, 43), while 1-year follow-ups of chimpanzees infected with HCV molecular clones have demonstrated lower substitution rates in E2 (24; J. Bukh, M. Yanagi, S. U. Emerson, and R. H. Purcell, Abstr. Fifth International Meeting on Hepatitis C Virus and Related Viruses: Molecular Virology and Pathogenesis, abstr. 28, 1998). These different rates could be due to a variety of factors, including differences in the complexity of the inoculum, duration of follow-up, or possibly the subtype. In the two studies with higher rates, the infecting subtype was 1b, while our study and the studies of molecular clones involved subtype 1a. Although too little is understood about the factors that affect sequence evolution, our data demonstrate that chronic HCV infection need not result in the accumulation of nonsynonymous mutations. This finding implies that immunodominant domains can be identified by examination of nonsynonymous change in a quasispecies, an important adjunct to existing measurements of the host-virus interaction.
As shown in Fig. 4, the nonsynonymous substitution rate observed for human subject H was intermediate between the rates of the other humans and those of the chimpanzees. Because the H77 strain was the inoculum for animal P1, the low rate of substitution for animal P2 might be attributed to some characteristic of the H77 strain. However, this would not explain the similar rate found in animal x304. In addition, the rate obtained in this study from patient H is based on a 22-year sampling interval, and saturation at nonsynonymous sites may have occurred (26).
The possibility of PCR contamination was carefully evaluated. Negative control samples were carried through every reaction and were consistently negative, and the highly diverse human samples were processed concurrently with the much less diverse chimpanzee samples. Also, while at least one of the majority clonotype sequences from each chimpanzee was consistently identical to H77, the minority clonotype sequences consistently revealed differences, in accordance with a quasispecies rather than H77 contamination. In addition, the same minor variants were frequently observed in sequential animals in the passage (Fig. 3B). If these differences had been due to misincorporations during amplification and cloning, a more random distribution of variants would have been expected.
Because we found that dN/dS is low in chimpanzees and strong negative selection is unlikely, these results indicate that positive selection pressure on the HCV quasispecies is weaker in chimpanzees than in humans. These findings have important implications for interpretation of data obtained using the chimpanzee model of HCV infection, and they support the prediction that a quasispecies under reduced selective pressure will undergo reduced change in the master sequence.
| |
ACKNOWLEDGMENTS |
|---|
This study was supported by NIH grants IU19 AI-40035 and P51 RR13986. The ALIVE cohort is supported by NIH grants DA04334 and DA08009.
We thank Harvey Alter for generously providing sera from subject H and John Ticehurst for many helpful discussions.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Division of Infectious Diseases, 720 Rutland Ave., Ross 1159, Baltimore, MD 21205. Phone: (410) 955-0349. Fax: (410) 955-7889. E-mail: sray{at}jhmi.edu.
Present address: Department of Microbiology and Immunology,
University of Texas Medical Branch, Galveston, TX 77555.
Present address: Department of Infectious Diseases, Southwest
Hospital, Third Military Medical University, Chongqing, Peoples' Republic of China.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Agnello, V., G. Abel, G. B. Knight, and E. Muchmore. 1998. Detection of widespread hepatocyte infection in chronic hepatitis C. Hepatology 28:573-584[CrossRef][Medline]. |
| 2. | Alter, H. J., R. H. Purcell, P. V. Holland, and H. Popper. 1978. Transmissible agent in non-A, non-B hepatitis. Lancet i:459-463. |
| 3. | Alter, M. J., H. S. Margolis, K. Krawczynski, F. N. Judson, A. Mares, W. J. Alexander, P. Y. Hu, J. K. Miller, M. A. Gerber, R. E. Sampliner, E. Meeks, and M. J. Beach. 1992. The natural history of community acquired hepatitis C in the United States. N. Engl. J. Med. 327:1899-1905[Abstract]. |
| 4. | Anonymous. 1997. Hepatitis C: global prevalence. Weekly Epidemiol. Rec. 72:341-348[Medline]. |
| 5. |
Bassett, S. E.,
K. M. Brasky, and R. E. Lanford.
1998.
Analysis of hepatitis C virus-inoculated chimpanzees reveals unexpected clinical profiles.
J. Virol.
72:2589-2599 |
| 6. |
Bassett, S. E.,
D. L. Thomas,
K. M. Brasky, and R. E. Lanford.
1998.
Viral persistence, antibody to E1 and E2 and HVR-1 sequence stability in hepatitis C virus-inoculated chimpanzees.
J. Virol.
73:1118-1126 |
| 7. | Booth, J. C., U. Kumar, D. Webster, J. Monjardino, and H. C. Thomas. 1998. Comparison of the rate of sequence variation in the hypervariable region of E2/NS1 region of hepatitis C virus in normal and hypogammaglobulinemic patients. Hepatology 27:223-227[CrossRef][Medline]. |
| 8. | Centers for Disease Control and Prevention. 1998. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Morbid. Mortal. Weekly Rep. 47:1-39[Medline]. |
| 9. |
Choo, Q. L.,
K. H. Richman,
J. H. Han,
K. Berger,
C. Lee,
C. Gallegos,
D. Coit,
A. Medina-Selby,
P. J. Barr,
A. J. Weiner,
D. W. Bradley,
G. Kuo, and M. Houghton.
1991.
Genetic organization and diversity of the hepatitis C virus.
Proc. Natl. Acad. Sci. USA
88:2451-2455 |
| 10. |
Domingo, E.,
E. Martinez-Salas,
F. Sobrino,
J. C. de la Torre,
A. Portela,
J. Ortin,
C. Lopez-Galindez,
P. Perez-Brena,
N. Villanueva, and R. Najera.
1985.
The quasispecies (extremely heterogeneous) nature of viral RNA genome populations: biological relevance a review.
Gene
40:1-8[CrossRef][Medline].
|
| 11. | Domingo, E., D. Sabo, T. Taniguchi, and C. Weissmann. 1978. Nucleotide sequence heterogeneity of an RNA phage population. Cell 13:735-744[CrossRef][Medline]. |
| 12. | Eigen, M. 1971. Self organization of matter and the evolution of biological macromolecules. Naturwissenschaften 58:465-523[CrossRef][Medline]. |
| 13. | Evans, D. T., D. H. O'Connor, P. Jing, J. L. Dzuris, J. Sidney, J. da Silva, T. M. Allen, H. Horton, J. E. Venham, R. A. Rudersdorf, T. Vogel, C. D. Pauza, R. E. Bontrop, R. DeMars, A. Sette, A. L. Hughes, and D. I. Watkins. 1999. Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef. Nat. Med. 5:1270-1276[CrossRef][Medline]. |
| 14. | Farci, P., H. J. Alter, S. Govindarajan, D. C. Wong, R. Engle, R. R. Lesniewski, I. K. Mushahwar, S. M. Desai, R. H. Miller, and N. Ogata. 1992. Lack of protective immunity against reinfection with hepatitis C virus. Eur. J. Biochem. 258:135-140. |
| 15. | Farci, P., H. J. Alter, D. Wong, R. H. Miller, J. W. Shih, B. Jett, and R. H. Purcell. 1991. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N. Engl. J. Med. 325:98-104[Abstract]. |
| 16. |
Farci, P.,
A. Shimoda,
D. Wong,
T. Cabezon,
D. De Gioannis,
A. Strazzera,
Y. Shimizu,
M. Shapiro,
H. J. Alter, and R. H. Purcell.
1996.
Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein.
Proc. Natl. Acad. Sci. USA
93:15394-15399 |
| 17. | Feinstone, S. M., H. J. Alter, H. P. Dienes, Y. Shimizu, H. Popper, D. Blackmore, D. Sly, W. T. London, and R. H. Purcell. 1981. Non-A, non-B hepatitis in chimpanzees and marmosets. J. Infect. Dis. 144:588-598[Medline]. |
| 18. | Felsenstein, J. 1985. Confidence limits on phylogenies: an approach using the bootstrap. Evolution 39:783-791[CrossRef]. |
| 19. |
Felsenstein, J.
1989.
PHYLIP phylogeny inference package (version 3.2).
Cladistics
5:164-166.
|
| 20. | Gretch, D. R., S. J. Polyak, J. J. Wilson, R. L. Carithers, Jr., J. D. Perkins, and L. Corey. 1996. Tracking hepatitis C virus quasispecies major and minor variants in symptomatic and asymptomatic liver transplant recipients. J. Virol. 70:7622-7631[Abstract]. |
| 21. | Hadziyannis, E., M. W. Fried, and F. S. Nolte. 1997. Evaluation of two methods for quantitation of hepatitis C virus RNA. Mol. Diagn. 2:39-46[CrossRef][Medline]. |
| 22. |
Kato, N.,
Y. Ootsuyama,
H. Sekiya,
S. Ohkoshi,
T. Nakazawa,
M. Hijikata, and K. Shimotohno.
1994.
Genetic drift in hypervariable region 1 of the viral genome in persistent hepatitis C virus infection.
J. Virol.
68:4776-4784 |
| 23. | Kato, N., Y. Ootsuyama, T. Tanaka, M. Nakagawa, T. Nakazawa, K. Muraiso, S. Ohkoshi, M. Hijikata, and K. Shimotohno. 1992. Marked sequence diversity in the putative envelope proteins of hepatitis C viruses. Virus Res. 22:107-123[CrossRef][Medline]. |
| 24. |
Major, M. E.,
K. Mihalik,
J. Fernandez,
J. Seidman,
D. Kleiner,
A. A. Kolykhalov,
C. M. Rice, and S. M. Feinstone.
1999.
Long-term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus.
J. Virol.
73:3317-3325 |
| 25. |
Martell, M.,
J. I. Esteban,
J. Quer,
J. Genesca,
A. Weiner,
R. Esteban,
Guardia, and J. Gomez.
1992.
Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution.
J. Virol.
66:3225-3229 |
| 26. |
McAllister, J.,
C. Casino,
F. Davidson,
J. Power,
E. Lawlor,
P. L. Yap,
P. Simmonds, and D. B. Smith.
1998.
Long-term evolution of the hypervariable region of hepatitis C virus in a common-source-infected cohort.
J. Virol.
72:4893-4905 |
| 27. | Nei, M., and T. Gojobori. 1986. Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions. Mol. Biol. Evol. 3:418-426[Abstract]. |
| 28. | Ni, Y. H., M. H. Chang, P. J. Chen, H. Y. Hsu, T. W. Lu, K. H. Lin, and D. T. Lin. 1999. Decreased diversity of hepatitis C virus quasispecies during bone marrow transplantation. J. Med. Virol. 58:132-138[CrossRef][Medline]. |
| 29. |
Ogata, N.,
H. J. Alter,
R. H. Miller, and R. H. Purcell.
1991.
Nucleotide sequence and mutation rate of the H strain of hepatitis C virus.
Proc. Natl. Acad. Sci. USA
88:3392-3396 |
| 30. | Okamoto, H., M. Kojima, S. Okada, H. Yoshizawa, H. Iizuka, T. Tanaka, E. E. Muchmore, D. A. Peterson, Y. Ito, and S. Mishiro. 1992. Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability. Virology 190:894-899[CrossRef][Medline]. |
| 31. |
Pawlotsky, J. M.,
G. Germanidis,
P. O. Frainais,
M. Bouvier,
A. Soulier,
M. Pellerin, and D. Dhumeaux.
1999.
Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy.
J. Virol.
73:6490-6499 |
| 32. | Phillips, R. E., S. Rowland-Jones, D. F. Nixon, F. M. Gotch, J. P. Edwards, A. O. Ogunlesi, J. G. Elvin, J. A. Rothbard, C. R. Bangham, and C. R. Rizza. 1991. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 354:453-459[CrossRef][Medline]. |
| 33. |
Ray, S. C.,
Y. M. Wang,
O. Laeyendecker,
J. Ticehurst,
S. A. Villano, and D. L. Thomas.
1998.
Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as decoy.
J. Virol.
73:2938-2946 |
| 34. | Roth, W. K., J. H. Lee, B. Rüster, and S. Zeuzem. 1996. Comparison of two quantitative hepatitis C virus reverse transcriptase PCR assays. J. Clin. Microbiol. 34:261-264[Abstract]. |
| 35. |
Shimizu, Y. K.,
M. Hijikata,
A. Iwamoto,
H. J. Alter,
R. H. Purcell, and H. Yoshikura.
1994.
Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses.
J. Virol.
68:1494-1500 |
| 36. | Shimizu, Y. K., H. Igarashi, T. Kiyohara, T. Cabezon, P. Farci, R. H. Purcell, and H. Yoshikura. 1996. A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures. Virology 223:409-412[CrossRef][Medline]. |
| 37. |
Shimizu, Y. K.,
A. J. Weiner,
J. Rosenblatt,
D. C. Wong,
M. Shapiro,
T. Popkin,
M. Houghton,
H. J. Alter, and R. H. Purcell.
1990.
Early events in hepatitis C virus infection of chimpanzees.
Proc. Natl. Acad. Sci. USA
87:6441-6444 |
| 38. | Smith, D. B., J. McAllister, C. Casino, and P. Simmonds. 1997. Virus `quasispecies': making a mountain out of a molehill? J. Gen. Virol. 78:1511-1519[Medline]. |
| 39. | Smith, D. B., and P. Simmonds. 1997. Characteristics of nucleotide substitution in the hepatitis C virus genome: constraints on sequence change in coding regions at both ends of the genome. J. Mol. Evol. 45:238-246[CrossRef][Medline]. |
| 40. | Steinhauer, D. A., and J. J. Holland. 1987. Rapid evolution of RNA viruses. Annu. Rev. Microbiol. 41:409-433[CrossRef][Medline]. |
| 41. |
Tong, M. J.,
N. S. El-Farra,
A. R. Reikes, and R. L. Co.
1995.
Clinical outcomes after transfusion-associated hepatitis C.
N. Engl. J. Med.
332:1463-1466 |
| 42. | Toyoda, H., Y. Fukuda, Y. Koyama, J. Takamatsu, H. Saito, and T. Hayakawa. 1997. Effect of immunosuppression on composition of quasispecies population of hepatitis C virus in patients with chronic hepatitis C coinfected with human immunodeficiency virus. J. Hepatol. 26:975-982[CrossRef][Medline]. |
| 43. | van Doorn, L. J., I. Capriles, G. Maertens, R. DeLeys, K. Murray, T. Kos, H. Schellekens, and W. Quint. 1995. Sequence evolution of the hypervariable region in the putative envelope region E2/NS1 of hepatitis C virus is correlated with specific humoral immune responses. J. Virol. 69:773-778[Abstract]. |
| 44. | Villano, S. A., D. Vlahov, K. E. Nelson, S. Cohn, and D. L. Thomas. 1999. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 29:908-914[CrossRef][Medline]. |
| 45. | Villano, S. A., D. Vlahov, K. E. Nelson, C. M. Lyles, S. Cohn, and D. L. Thomas. 1997. Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J. Clin. Microbiol. 35:3274-3277[Abstract]. |
| 46. | Vlahov, D., J. C. Anthony, A. Muñoz, J. Margolik, D. D. Celentano, L. Solomon, and B. F. Polk. 1991. The ALIVE Study: a longitudinal study of HIV-1 infection in intravenous drug users: description of methods. J. Drug Issues 21:759-776. |
| 47. | Wain-Hobson, S. 1996. Running the gamut of retroviral variation. Trends Microbiol. 4:135-141[CrossRef][Medline]. |
| 48. |
Wang, Y. M.,
S. C. Ray,
O. Laeyendecker,
J. R. Ticehurst, and D. L. Thomas.
1998.
Assessment of hepatitis C virus sequence complexity by electrophoretic mobilities of both single- and double-stranded DNAs.
J. Clin. Microbiol.
36:2982-2989 |
| 49. |
Weiner, A. J.,
H. M. Geysen,
C. Christopherson,
J. E. Hall,
T. J. Mason,
G. Saracco,
F. Bonino,
K. Crawford,
C. D. Marion,
K. A. Crawford, et al.
1992.
Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections.
Proc. Natl. Acad. Sci. USA
89:3468-3472 |
| 50. | Wolinsky, S. M., B. T. Korber, A. U. Neumann, M. Daniels, K. J. Kunstman, A. J. Whetsell, M. R. Furtado, Y. Cao, D. D. Ho, and J. T. Safrit. 1996. Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Eur. J. Biochem. 272:537-542. |
| 51. |
Wyatt, C. A.,
L. Andrus,
B. Brotman,
F. Huang,
D. H. Lee, and A. M. Prince.
1998.
Immunity in chimpanzees chronically infected with hepatitis C virus: role of minor quasispecies in reinfection.
J. Virol.
72:1725-1730 |
| 52. | Xie, Z. C., J. I. Riezu-Boj, J. J. Lasarte, J. Guillen, J. H. Su, M. P. Civeira, and J. Prieto. 1998. Transmission of hepatitis C virus infection to tree shrews. Virology 244:513-520[CrossRef][Medline]. |
| 53. | Zibert, A., E. Schreier, and M. Roggendorf. 1995. Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment. Virology 208:653-661[CrossRef][Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|